Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Esophageal Squamous Cell Carcinoma 8Esophageal Neoplasms 4Squamous Cell Carcinoma of Head and Neck 2Uterine Neoplasms 1Thyroid Neoplasms 1Thymoma 1Thymic epithelial tumor 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Mouth Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Sunitinib 5pembrolizumab 4Paclitaxel 4Carboplatin 4Radiotherapy 3Cyclophosphamide 3Cisplatin 3selinexor 2lenvatinib 2Taxes 2Ramucirumab 2Octreotide 2N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide 2Methylprednisolone 2Erlotinib Hydrochloride 2Chemoradiotherapy 2zimberelimab 1saracatinib 1regorafenib 1epacadostat 1envafolimab 1belinostat 1avelumab 1atezolizumab 1amrubicin 1alovudine 1TP protocol 1Radiofrequency Ablation 1Radiation Dose Hypofractionation 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Thymoma × TP protocol × Clear all
NCT00818090 2013-04-12

Paclitaxel and Cisplatin for Thymic Neoplasm

Korean Cancer Study Group

Phase 2 Terminated
39 enrolled
Thoracic

Thymic epithelial tumor, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡